Cynda(SH:603086)2026-01-26 08:30Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between 135 million and 155 million yuan, marking a turnaround from a loss in the previous year[3]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between 120 million and 140 million yuan[5]. - In 2024, the company reported a net loss attributable to shareholders of 25.88 million yuan, compared to the expected profit in 2025[7]. Product Performance - The significant increase in sales price of the main product, Acetochlor, has notably improved the overall gross margin[9]. - The successful launch and sales of the new product series, Pyrazole Quinclorac, have further boosted the gross margin of domestic formulations[9]. Operational Efficiency - The company has implemented operational reforms and a gross profit distribution plan to enhance cost control and overall operational efficiency[9]. - There are currently no major uncertainties affecting the accuracy of the profit forecast[10]. - The forecast data is preliminary and subject to confirmation in the official 2025 annual report[11].